Opioid Induced Constipation Drug Market – Global Industry Analysis and Forecast (2022-2029)


Opioid Induced Constipation Drug Market was valued at US$ 2.36 Mn in 2021 and is expected to reach US$ 3.83 Mn by 2029 at a CAGR of 6.2%.

The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding the global opioid induced constipation drug market dynamics, structure by identifying and analysing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence.

Global Opioid Induced Constipation MarketTo know about the Research Methodology :- Request Free Sample Report

The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address questions of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in the global opioid induced constipation drug market.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

The number of patients suffering from opioid induced constipation is growing across the globe. Close to 100 mn U.S. patients in 2013 were suffering from opioid induced constipation, according to the American Academy of Pain Medicine. They added that this number is anticipated to increase as the number of people consuming opioid drugs increases. With an increasing awareness of the commercial availability of a large type of opioid drugs, people have resorted to using them for longer terms to treat chronic pains.

Increasing incidences of diseases associated with old age, impaired body functions, and rise in the use of medicines such as antidepressants and anticholinergic have collectively led to a high prevalence of constipation among the elderly population. This drives growth in the opioid induced constipation market globally. The use of laxatives for opioid induced constipation is a major challenge that is reducing sales of approved drugs meant for the treatment of opioid induced constipation.

Lubiprostone segment is leading the global opioid induced constipation drug market. Lubiprostone under the brand name Amitiza is indicated for treating opioid induced constipation drug, where it major indication is for chronic idiopathic constipation (CIC). Lubiprostone is projected that the segment will take over the market share of methylnaltrexone bromide. Moreover, naloxegol is expected to grow at highest CAGR over the forecast period. The drug is under testing for many patient types such as pregnant women and patients less than 17 years of age. So, future approvals are expected to lead the market.

Region-wise, North America is the dominant regional opioid induced constipation drugs market through the forecast period. Early bird approval of opioid induced constipation drugs by the USFDA and high consumption of opioids in the US is the prime growth factors for the opioid induced constipation drugs market in North America. Besides, Germany, UK, and Spain are the major countries setting the market dynamics in Europe. Overall, the developed countries across the world, predominantly North America and Europe are the key consumers of opioid induced constipation drugs.

Scope of Global Opioid Induced Constipation Drug Market: Inquire before buying






Global Opioid Induced Constipation Market




Report Coverage
Details




Base Year:
2021
Forecast Period:
2022-2029




Historical Data:
2017 to 2021
Market Size in 2021:
US $ 2.36 Mn.




Forecast Period 2022 to 2029 CAGR:
6.2%
Market Size in 2029:
US $ 3.83Mn.




 Segments Covered:
by Prescription
• Prescribed
• Over The Counter




by Type
• Methylnaltrexone Bromide
• Lubiprostone
• Naloxegol
• Naldemedine
• Docusate Sodium
• Others






Opioid Induced Constipation Drug Market, by Region

• North America
• Europe
• Asia Pacific
• Middle East and Africa
• South America

Key players operating in Global Opioid Induced Constipation Drug Market

• GlaxoSmithKline, Inc.
• AstraZeneca plc, Inc.
• Pfizer, Inc.
• S.L.A. Pharma AG
• AIKO Biotechnology
• Cubist Pharmaceuticals
• Salix Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• Shionogo & Co Ltd.
• Daiichi Sankyo Co., Ltd.
• Ironwood Pharmaceuticals, Inc.
• Progenics Pharmaceuticals, Inc.
• Sucampo Pharmaceuticals, Inc.
• Synergy Pharmaceuticals, Inc.

Frequently Asked Questions:

1. Which region has the largest share in Global Opioid Induced Constipation Market?
Ans: Asia Pacific region holds the highest share in 2021.

2. What is the growth rate of Global Opioid Induced Constipation Market?
Ans: The Global Opioid Induced Constipation Drug Market is growing at a CAGR of 6.2% during forecasting period 2022-2029.

3. What is scope of the Global Opioid Induced Constipation Market report?
Ans: Global Opioid Induced Constipation Drug Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. What is the study period of this market?
Ans: The Global Opioid Induced Constipation Drug Market is studied from 2021 to 2029. 





Global Opioid Induced Constipation Drug Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources

3. Executive Summary: Global Opioid Induced Constipation Drug Market, by Market Value (US$ Mn)

4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies

5. Supply Side and Demand Side Indicators

6. Global Opioid Induced Constipation Drug Market Analysis and Forecast
6.1. Global Opioid Induced Constipation Drug Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Opioid Induced Constipation Drug Market Analysis and Forecast, by Drug Type
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Opioid Induced Constipation Drug Market Value Share Analysis, by Drug Type
7.4. Global Opioid Induced Constipation Drug Market Size (US$ Mn) Forecast, by Drug Type
7.5. Global Opioid Induced Constipation Drug Market Analysis, by Drug Type
7.6. Global Opioid Induced Constipation Drug Market Attractiveness Analysis, by Drug Type

8. Global Opioid Induced Constipation Drug Market Analysis and Forecast, by Prescription Type
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Opioid Induced Constipation Drug Market Value Share Analysis, by Prescription Type
8.4. Global Opioid Induced Constipation Drug Market Size (US$ Mn) Forecast, by Prescription Type
8.5. Global Opioid Induced Constipation Drug Market Analysis, by Prescription Type
8.6. Global Opioid Induced Constipation Drug Market Attractiveness Analysis, by Prescription Type

9. Global Opioid Induced Constipation Drug Market Analysis, by Region
9.1. Global Opioid Induced Constipation Drug Market Value Share Analysis, by Region
9.2. Global Opioid Induced Constipation Drug Market Size (US$ Mn) Forecast, by Region
9.3. Global Opioid Induced Constipation Drug Market Attractiveness Analysis, by Region

10. North America Opioid Induced Constipation Drug Market Analysis
10.1. Key Findings
10.2. North America Opioid Induced Constipation Drug Market Overview
10.3. North America Opioid Induced Constipation Drug Market Value Share Analysis, by Drug Type
10.4. North America Opioid Induced Constipation Drug Market Forecast, by Drug Type
10.4.1. Methylnaltrexone Bromide
10.4.2. Lubiprostone,
10.4.3. Naloxegol
10.4.4. Naldemedine,
10.4.5. Docusate Sodium,
10.4.6. Others
10.5. North America Opioid Induced Constipation Drug Market Value Share Analysis, by Prescription Type
10.6. North America Opioid Induced Constipation Drug Market Forecast, by Prescription Type
10.6.1. Prescribed
10.6.2. Over The Counter
10.7. North America Opioid Induced Constipation Drug Market Value Share Analysis, by Country
10.8. North America Opioid Induced Constipation Drug Market Forecast, by Country
10.8.1. U.S.
10.8.2. Canada
10.9. North America Opioid Induced Constipation Drug Market Analysis, by Country
10.10. U.S. Opioid Induced Constipation Drug Market Forecast, by Drug Type
10.10.1. Methylnaltrexone Bromide
10.10.2. Lubiprostone,
10.10.3. Naloxegol
10.10.4. Naldemedine,
10.10.5. Docusate Sodium,
10.10.6. Others
10.11. U.S. Opioid Induced Constipation Drug Market Forecast, by Prescription Type
10.11.1. Prescribed
10.11.2. Over The Counter
10.12. Canada Opioid Induced Constipation Drug Market Forecast, by Drug Type
10.12.1. Methylnaltrexone Bromide
10.12.2. Lubiprostone,
10.12.3. Naloxegol
10.12.4. Naldemedine,
10.12.5. Docusate Sodium,
10.12.6. Others
10.13. Canada Opioid Induced Constipation Drug Market Forecast, by Prescription Type
10.13.1. Prescribed
10.13.2. Over The Counter
10.14. North America Opioid Induced Constipation Drug Market Attractiveness Analysis
10.14.1. By Drug Type
10.14.2. By Prescription Type
10.15. PEST Analysis
10.16. Key Trends
10.17. Key Development

11. Europe Opioid Induced Constipation Drug Market Analysis
11.1. Key Findings
11.2. Europe Opioid Induced Constipation Drug Market Overview
11.3. Europe Opioid Induced Constipation Drug Market Value Share Analysis, by Drug Type
11.4. Europe Opioid Induced Constipation Drug Market Forecast, by Drug Type
11.4.1. Methylnaltrexone Bromide
11.4.2. Lubiprostone,
11.4.3. Naloxegol
11.4.4. Naldemedine,
11.4.5. Docusate Sodium,
11.4.6. Others
11.5. Europe Opioid Induced Constipation Drug Market Value Share Analysis, by Prescription Type
11.6. Europe Opioid Induced Constipation Drug Market Forecast, by Prescription Type
11.6.1. Prescribed
11.6.2. Over The Counter
11.7. Europe Opioid Induced Constipation Drug Market Value Share Analysis, by Country
11.8. Europe Opioid Induced Constipation Drug Market Forecast, by Country
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Rest of Europe
11.9. Europe Opioid Induced Constipation Drug Market Analysis, by Country
11.10. Germany Opioid Induced Constipation Drug Market Forecast, by Drug Type
11.10.1. Methylnaltrexone Bromide
11.10.2. Lubiprostone,
11.10.3. Naloxegol
11.10.4. Naldemedine,
11.10.5. Docusate Sodium,
11.10.6. Others
11.11. Germany Opioid Induced Constipation Drug Market Forecast, by Prescription Type
11.11.1. Prescribed
11.11.2. Over The Counter
11.12. U.K. Opioid Induced Constipation Drug Market Forecast, by Drug Type
11.12.1. Methylnaltrexone Bromide
11.12.2. Lubiprostone,
11.12.3. Naloxegol
11.12.4. Naldemedine,
11.12.5. Docusate Sodium,
11.12.6. Others
11.13. U.K. Opioid Induced Constipation Drug Market Forecast, by Prescription Type
11.13.1. Prescribed
11.13.2. Over The Counter
11.14. France Opioid Induced Constipation Drug Market Forecast, by Drug Type
11.14.1. Methylnaltrexone Bromide
11.14.2. Lubiprostone,
11.14.3. Naloxegol
11.14.4. Naldemedine,
11.14.5. Docusate Sodium,
11.14.6. Others
11.15. France Opioid Induced Constipation Drug Market Forecast, by Prescription Type
11.15.1. Prescribed
11.15.2. Over The Counter
11.16. Italy Opioid Induced Constipation Drug Market Forecast, by Drug Type
11.16.1. Methylnaltrexone Bromide
11.16.2. Lubiprostone,
11.16.3. Naloxegol
11.16.4. Naldemedine,
11.16.5. Docusate Sodium,
11.16.6. Others
11.17. Italy Opioid Induced Constipation Drug Market Forecast, by Prescription Type
11.17.1. Prescribed
11.17.2. Over The Counter
11.18. Spain Opioid Induced Constipation Drug Market Forecast, by Drug Type
11.18.1. Methylnaltrexone Bromide
11.18.2. Lubiprostone,
11.18.3. Naloxegol
11.18.4. Naldemedine,
11.18.5. Docusate Sodium,
11.18.6. Others
11.19. Spain Opioid Induced Constipation Drug Market Forecast, by Prescription Type
11.19.1. Prescribed
11.19.2. Over The Counter
11.20. Rest of Europe Opioid Induced Constipation Drug Market Forecast, by Drug Type
11.20.1. Methylnaltrexone Bromide
11.20.2. Lubiprostone,
11.20.3. Naloxegol
11.20.4. Naldemedine,
11.20.5. Docusate Sodium,
11.20.6. Others
11.21. Rest of Europe Opioid Induced Constipation Drug Market Forecast, by Prescription Type
11.21.1. Prescribed
11.21.2. Over The Counter
11.22. Europe Opioid Induced Constipation Drug Market Attractiveness Analysis
11.22.1. By Drug Type
11.22.2. By Prescription Type
11.23. PEST Analysis
11.24. Key Trends
11.25. Key Development

12. Asia Pacific Opioid Induced Constipation Drug Market Analysis
12.1. Key Findings
12.2. Asia Pacific Opioid Induced Constipation Drug Market Overview
12.3. Asia Pacific Opioid Induced Constipation Drug Market Value Share Analysis, by Drug Type
12.4. Asia Pacific Opioid Induced Constipation Drug Market Forecast, by Drug Type
12.4.1. Methylnaltrexone Bromide
12.4.2. Lubiprostone,
12.4.3. Naloxegol
12.4.4. Naldemedine,
12.4.5. Docusate Sodium,
12.4.6. Others
12.5. Asia Pacific Opioid Induced Constipation Drug Market Value Share Analysis, by Prescription Type
12.6. Asia Pacific Opioid Induced Constipation Drug Market Forecast, by Prescription Type
12.6.1. Prescribed
12.6.2. Over The Counter
12.7. Asia Pacific Opioid Induced Constipation Drug Market Value Share Analysis, by Country
12.8. Asia Pacific Opioid Induced Constipation Drug Market Forecast, by Country
12.8.1. China
12.8.2. India
12.8.3. Japan
12.8.4. ASEAN
12.8.5. Rest of Asia Pacific
12.9. Asia Pacific Opioid Induced Constipation Drug Market Analysis, by Country
12.10. China Opioid Induced Constipation Drug Market Forecast, by Drug Type
12.10.1. Methylnaltrexone Bromide
12.10.2. Lubiprostone,
12.10.3. Naloxegol
12.10.4. Naldemedine,
12.10.5. Docusate Sodium,
12.10.6. Others
12.11. China Opioid Induced Constipation Drug Market Forecast, by Prescription Type
12.11.1. Prescribed
12.11.2. Over The Counter
12.12. India Opioid Induced Constipation Drug Market Forecast, by Drug Type
12.12.1. Methylnaltrexone Bromide
12.12.2. Lubiprostone,
12.12.3. Naloxegol
12.12.4. Naldemedine,
12.12.5. Docusate Sodium,
12.12.6. Others
12.13. India Opioid Induced Constipation Drug Market Forecast, by Prescription Type
12.13.1. Prescribed
12.13.2. Over The Counter
12.14. Japan Opioid Induced Constipation Drug Market Forecast, by Drug Type
12.14.1. Methylnaltrexone Bromide
12.14.2. Lubiprostone,
12.14.3. Naloxegol
12.14.4. Naldemedine,
12.14.5. Docusate Sodium,
12.14.6. Others
12.15. Japan Opioid Induced Constipation Drug Market Forecast, by Prescription Type
12.15.1. Prescribed
12.15.2. Over The Counter
12.16. ASEAN Opioid Induced Constipation Drug Market Forecast, by Drug Type
12.16.1. Methylnaltrexone Bromide
12.16.2. Lubiprostone,
12.16.3. Naloxegol
12.16.4. Naldemedine,
12.16.5. Docusate Sodium,
12.16.6. Others
12.17. ASEAN Opioid Induced Constipation Drug Market Forecast, by Prescription Type
12.17.1. Prescribed
12.17.2. Over The Counter
12.18. Rest of Asia Pacific Opioid Induced Constipation Drug Market Forecast, by Drug Type
12.18.1. Methylnaltrexone Bromide
12.18.2. Lubiprostone,
12.18.3. Naloxegol
12.18.4. Naldemedine,
12.18.5. Docusate Sodium,
12.18.6. Others
12.19. Rest of Asia Pacific Opioid Induced Constipation Drug Market Forecast, by Prescription Type
12.19.1. Prescribed
12.19.2. Over The Counter
12.20. Asia Pacific Opioid Induced Constipation Drug Market Attractiveness Analysis
12.20.1. By Drug Type
12.20.2. By Prescription Type
12.21. PEST Analysis
12.22. Key Trends
12.23. Key Development

13. Middle East & Africa Opioid Induced Constipation Drug Market Analysis
13.1. Key Findings
13.2. Middle East & Africa Opioid Induced Constipation Drug Market Overview
13.3. Middle East & Africa Opioid Induced Constipation Drug Market Value Share Analysis, by Drug Type
13.4. Middle East & Africa Opioid Induced Constipation Drug Market Forecast, by Drug Type
13.4.1. Methylnaltrexone Bromide
13.4.2. Lubiprostone,
13.4.3. Naloxegol
13.4.4. Naldemedine,
13.4.5. Docusate Sodium,
13.4.6. Others
13.5. Middle East & Africa Opioid Induced Constipation Drug Market Value Share Analysis, by Prescription Type
13.6. Middle East & Africa Opioid Induced Constipation Drug Market Forecast, by Prescription Type
13.6.1. Prescribed
13.6.2. Over The Counter
13.7. Middle East & Africa Opioid Induced Constipation Drug Market Value Share Analysis, by Country
13.8. Middle East & Africa Opioid Induced Constipation Drug Market Forecast, by Country
13.8.1. GCC
13.8.2. South Africa
13.8.3. Rest of Middle East & Africa
13.9. Middle East & Africa Opioid Induced Constipation Drug Market Analysis, by Country
13.10. GCC Opioid Induced Constipation Drug Market Forecast, by Drug Type
13.10.1. Methylnaltrexone Bromide
13.10.2. Lubiprostone,
13.10.3. Naloxegol
13.10.4. Naldemedine,
13.10.5. Docusate Sodium,
13.10.6. Others
13.11. GCC Opioid Induced Constipation Drug Market Forecast, by Prescription Type
13.11.1. Prescribed
13.11.2. Over The Counter
13.12. South Africa Opioid Induced Constipation Drug Market Forecast, by Drug Type
13.12.1. Methylnaltrexone Bromide
13.12.2. Lubiprostone,
13.12.3. Naloxegol
13.12.4. Naldemedine,
13.12.5. Docusate Sodium,
13.12.6. Others
13.13. South Africa Opioid Induced Constipation Drug Market Forecast, by Prescription Type
13.13.1. Prescribed
13.13.2. Over The Counter
13.14. Rest of Middle East & Africa Opioid Induced Constipation Drug Market Forecast, by Drug Type
13.14.1. Methylnaltrexone Bromide
13.14.2. Lubiprostone,
13.14.3. Naloxegol
13.14.4. Naldemedine,
13.14.5. Docusate Sodium,
13.14.6. Others
13.15. Rest of Middle East & Africa Opioid Induced Constipation Drug Market Forecast, by Prescription Type
13.15.1. Prescribed
13.15.2. Over The Counter
13.16. Middle East & Africa Opioid Induced Constipation Drug Market Attractiveness Analysis
13.16.1. By Drug Type
13.16.2. By Prescription Type
13.17. PEST Analysis
13.18. Key Trends
13.19. Key Development

14. South America Opioid Induced Constipation Drug Market Analysis
14.1. Key Findings
14.2. South America Opioid Induced Constipation Drug Market Overview
14.3. South America Opioid Induced Constipation Drug Market Value Share Analysis, by Drug Type
14.4. South America Opioid Induced Constipation Drug Market Forecast, by Drug Type
14.4.1. Methylnaltrexone Bromide
14.4.2. Lubiprostone,
14.4.3. Naloxegol
14.4.4. Naldemedine,
14.4.5. Docusate Sodium,
14.4.6. Others
14.5. South America Opioid Induced Constipation Drug Market Value Share Analysis, by Prescription Type
14.6. South America Opioid Induced Constipation Drug Market Forecast, by Prescription Type
14.6.1. Prescribed
14.6.2. Over The Counter
14.7. South America Opioid Induced Constipation Drug Market Value Share Analysis, by Country
14.8. South America Opioid Induced Constipation Drug Market Forecast, by Country
14.8.1. Brazil
14.8.2. Mexico
14.8.3. Rest of South America
14.9. South America Opioid Induced Constipation Drug Market Analysis, by Country
14.10. Brazil Opioid Induced Constipation Drug Market Forecast, by Drug Type
14.10.1. Methylnaltrexone Bromide
14.10.2. Lubiprostone,
14.10.3. Naloxegol
14.10.4. Naldemedine,
14.10.5. Docusate Sodium,
14.10.6. Others
14.11. Brazil Opioid Induced Constipation Drug Market Forecast, by Prescription Type
14.11.1. Prescribed
14.11.2. Over The Counter
14.12. Mexico Opioid Induced Constipation Drug Market Forecast, by Drug Type
14.12.1. Methylnaltrexone Bromide
14.12.2. Lubiprostone,
14.12.3. Naloxegol
14.12.4. Naldemedine,
14.12.5. Docusate Sodium,
14.12.6. Others
14.13. Mexico Opioid Induced Constipation Drug Market Forecast, by Prescription Type
14.13.1. Prescribed
14.13.2. Over The Counter
14.14. Rest of South America Opioid Induced Constipation Drug Market Forecast, by Drug Type
14.14.1. Methylnaltrexone Bromide
14.14.2. Lubiprostone,
14.14.3. Naloxegol
14.14.4. Naldemedine,
14.14.5. Docusate Sodium,
14.14.6. Others
14.15. Rest of South America Opioid Induced Constipation Drug Market Forecast, by Prescription Type
14.15.1. Prescribed
14.15.2. Over The Counter
14.16. South America Opioid Induced Constipation Drug Market Attractiveness Analysis
14.16.1. By Drug Type
14.16.2. By Prescription Type
14.17. PEST Analysis
14.18. Key Trends
14.19. Key Development

15. Company Profiles
15.1. Market Share Analysis, by Company
15.2. Competition Matrix
15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
15.2.2. New Product Launches and Product Enhancements
15.2.3. Market Consolidation
15.2.3.1. M&A by Regions, Investment and Applications
15.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
15.3. Company Profiles: Key Players
15.3.1. GlaxoSmithKline, Inc.,
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategy
15.3.1.5. Recent Developments
15.3.1.6. Manufacturing Footprint
15.3.2. AstraZeneca plc, Inc.
15.3.3. Pfizer, Inc.
15.3.4. S.L.A. Pharma AG
15.3.5. AIKO Biotechnology
15.3.6. Cubist Pharmaceuticals
15.3.7. Salix Pharmaceuticals, Inc.
15.3.8. Takeda Pharmaceutical Company Limited
15.3.8. Shionogo & Co Ltd.
15.3.9. Daiichi Sankyo Co., Ltd.
15.3.10. Ironwood Pharmaceuticals, Inc.
15.3.11. Progenics Pharmaceuticals, Inc.
15.3.12. Sucampo Pharmaceuticals, Inc.
15.3.13. Synergy Pharmaceuticals, Inc.

16. Primary Key Insights

About This Report

Report ID 25516
Category Healthcare
Published Date Oct 2022
Updated Date